ANTIMALARIAL DRUG COMBINATION THERAPY Report of a WHO Technical Consultation

The designations employed and the presentation of the material in this document, including maps and tables do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omission excepted, the names of proprietary products are distinguished by initial capital letters. The authors wish to recognise the contributions made to the writing of this report at country level by Ministries of Health and other partners, Regional Offices of WHO, and at a global level by mission reports, partners and the RBM team. 4 ANTIMALARIAL DRUG COMBINATION THERAPY ABBREVIATIONS ACT artemisinin-based combination therapy AIDS acquired immunodeficiency syndrome AQ amodiaquine CQ chloroquine CT combination therapy DHA dihydroartemisinin DRAs drug regulatory authorities G6PD glucose-6-phosphate dehydrogenase GMP good manufacturing practice HIV human immuno-deficiency virus P. falciparum Plasmodium falciparum P. vivax Plasmodium vivax RBM Roll Back Malaria SP sulfadoxine-pyrimethamine TDR Special programme for Research and Training in Tropical Diseases WHO World Health Organization

[1]  The use of essential drugs. , 2000, World Health Organization technical report series.

[2]  C. Curtis,et al.  Resistance to pyrimethamine/sulfadoxine in Plasmodium falciparum in 12 villages in north east Tanzania and a test of chlorproguanil/dapsone. , 1997, Acta tropica.

[3]  W. Wernsdorfer,et al.  In vitro sensitivity of Plasmodium falciparum and clinical response to lumefantrine (benflumetol) and artemether. , 2000, British journal of clinical pharmacology.

[4]  W. Peters,et al.  The prevention of antimalarial drug resistance. , 1990, Pharmacology & therapeutics.

[5]  B. Greenwood,et al.  Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine as a treatment for uncomplicated malaria--a systematic review. , 1998, Annals of tropical medicine and parasitology.

[6]  K. Rieckmann,et al.  Response of Plasmodium falciparum infections to pyrimethamine-sulfadoxine in Thailand. , 1987, The American journal of tropical medicine and hygiene.

[7]  K. Neftel,et al.  Amodiaquine induced agranulocytosis and liver damage. , 1986, British medical journal.

[8]  R. Price,et al.  Effects of artemisinin derivatives on malaria transmissibility , 1996, The Lancet.

[9]  H. Webster,et al.  Mefloquine-resistant falciparum malaria on the Thai-Burmese border , 1991, The Lancet.

[10]  N. White,et al.  Randomized Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in Treatment of MultidrugResistant Falciparum Malaria , 1998, Antimicrobial Agents and Chemotherapy.

[11]  N. White,et al.  Drug resistance in malaria. , 1998, British medical bulletin.

[12]  A. Schapira,et al.  Evaluation of four therapeutic regimens for falciparum malaria in Mozambique, 1986. , 1988, Bulletin of the World Health Organization.

[13]  N. White.  COMBINATION TREATMENT FOR FALCIPARUM PROPHYLAXIS , 1987, The Lancet.

[14]  H. Webster,et al.  Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. , 1996, The American journal of tropical medicine and hygiene.

[15]  P. Olliaro,et al.  Averting a malaria disaster , 1999, The Lancet.

[16]  N. White,et al.  Delaying antimalarial drug resistance with combination chemotherapy. , 1999, Parassitologia.

[17]  P. Phillips-Howard,et al.  Serious Adverse Drug Reactions to Pyrimethamine-Sulphadoxine, Pyrimethamine-Dapsone and to Amodiaquine in Britain , 1990, Journal of the Royal Society of Medicine.

[18]  G. Cook.  Practical chemotherapy of malaria. Report of a WHO Scientific Group. , 1990, World Health Organization technical report series.

[19]  W. Wernsdorfer,et al.  High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania. , 1996, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[20]  K. Marsh.  Malaria disaster in Africa , 1998, The Lancet.

[21]  N. White,et al.  Antimalarial drug resistance: the pace quickens. , 1992, The Journal of antimicrobial chemotherapy.

[22]  K. Mogale,et al.  Mefloquine-induced psychosis. , 2000, The Pediatric infectious disease journal.

[23]  T. Wang.  Follow-up observation on the therapeutic effects and remote reactions of artemisinin (Qinghaosu) and artemether in treating malaria in pregnant woman. , 1989, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.

[24]  J. M. Kofi Ekue,et al.  A double-blind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria. , 1983, Bulletin of the World Health Organization.

[25]  G. Edwards,et al.  FREQUENCY OF SEVERE NEUTROPENIA ASSOCIATED WITH AMODIAQUINE PROPHYLAXIS AGAINST MALARIA , 1986, The Lancet.

[26]  Ian M Hastings,et al.  Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. , 2004, The American journal of tropical medicine and hygiene.

[27]  I. Potasman,et al.  Neuropsychiatric problems in 2,500 long-term young travelers to the tropics. , 2006, Journal of travel medicine.

[28]  N. White,et al.  Preventing antimalarial drug resistance through combinations. , 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[29]  Guoqiao Li,et al.  Clinical trials of artemisinin and its derivatives in the treatment of malaria in China. , 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[30]  J. Simpson,et al.  Artemisinin derivatives in the treatment of falciparum malaria in pregnancy. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[31]  W. Ouyang,et al.  Effectiveness of amodiaquine, sulfadoxine-pyrimethamine, and combinations of these drugs for treating chloroquine-resistant falciparum malaria in Hainan Island, China. , 1988, Bulletin of the World Health Organization.

[32]  N. White,et al.  No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. , 1999, American Journal of Tropical Medicine and Hygiene.

[33]  P. Olliaro,et al.  Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. , 1996, Parasitology today.

[34]  B. Greenwood,et al.  Early clinical failures after pyrimethamine-sulfadoxine treatment of uncomplicated falciparum malaria. , 1996, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[35]  B. Sadler,et al.  Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[36]  W. Wernsdorfer,et al.  A randomized, double-blind, comparative trial of a new oral combination of artemether and benflumetol (CGP 56697) with mefloquine in the treatment of acute Plasmodium falciparum malaria in Thailand. , 1999, The American journal of tropical medicine and hygiene.

[37]  Atovaquone and Proguanil for Plasmodium falciparum Malaria , 1996 .

[38]  R. Guiguemdé,et al.  Amodiaquine remains effective for treating uncomplicated malaria in west and central Africa. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[39]  T. Hien.  An overview of the clinical use of artemisinin and its derivatives in the treatment of falciparum malaria in Viet Nam. , 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[40]  K. Bojang,et al.  A trial of Fansidar plus chloroquine or Fansidar alone for the treatment of uncomplicated malaria in Gambian children. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[41]  R. Steketee,et al.  Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. , 1993, The Journal of infectious diseases.

[42]  C. Gillotin,et al.  PHARMACOKINETICS AND DISPOSITION , 1999 .

[43]  S. Jaffar,et al.  Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697. , 1997, The Journal of infectious diseases.

[44]  R. Price,et al.  Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. , 1995, Bulletin of the World Health Organization.

[45]  A. Breckenridge,et al.  The disposition of amodiaquine in Zambians and Nigerians with malaria. , 1990, British journal of clinical pharmacology.

[46]  Advances in malaria chemotherapy. Report of a WHO Scientific group. , 1984, World Health Organization technical report series.

[47]  W. Watkins,et al.  Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[48]  P. Garner,et al.  Systematic review of amodiaquine treatment in uncomplicated malaria , 1996, The Lancet.

[49]  W. Wernsdorfer,et al.  A symposium on containment of mefloquine-resistant falciparum malaria in Southeast Asia with special reference to border malaria. , 1994, The Southeast Asian journal of tropical medicine and public health.

[50]  N. White,et al.  Assessment of the pharmacodynamic properties of antimalarial drugs in vivo , 1997, Antimicrobial agents and chemotherapy.

[51]  S. Looareesuwan,et al.  Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. , 1999, The American journal of tropical medicine and hygiene.